
CLINICAL and MOLECULAR HEPATOLOGY

The forum for latest knowledge of hepatobiliary diseases



HCC incidence is decreasing in Korea but increasing in elderly

Early changes in biomarkers predict HBsAg response Baveno-VII predicts decompensation in cACLD





Letter to the Editor

https://doi.org/10.3350/cmh.2022.0328 Clinical and Molecular Hepatology 2023;29:168

Letter regarding "COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis"

Rujittika Mungmunpuntipantip¹ and Viroj Wiwanitkit²

¹Private Academic Consultant, Bangkok, Thailand; ²Department of Research Center, Chandigarh University, Punjab, India

Keywords: COVID-19; Vaccines; Liver

Dear Editor,

We would like to share ideas on "COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis." In contrast to liver transplant recipients, patients with chronic liver disease exhibited a good humoral response to the coronavirus disease 2019 (COVID-19) vaccination, according to Cheung et al. We also agree that COVID-19 is helpful in immunogenicity. The immunological response of a vaccine recipient with an underlying medical condition may be different from that of a healthy individual. Potential confounding factors must be taken into consideration while interpreting the current report. Prior asymptomatic COVID-19 infection is a possibility, and is not unusual. If there is no method to rule out prior cases of asymptomatic COVID-19, it would be challenging to evaluate the effectiveness of the vaccine.

Authors' contribution

RM: 50% ideas, writing, approval for submission; VW: 50% ideas, supervision, approval for submission

Conflicts of Interest -

The authors declare no conflicts of interest.

REFERENCES

- Cheung KS, Mok CH, Mao X, Zhang R, Hung IF, Seto WK, et al. COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: a meta-analysis. Clin Mol Hepatol 2022;28:890-911.
- Joob B, Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health 2020;53:70.

Corresponding author: Rujittika Mungmunpuntipantip

Private Academic Consultant, 111 Bangkok 122, Bangkok 103300, Thailand Tel: +66-22564133662, Fax: +66-22564133662, E-mail: rujittika@gmail.com https://orcid.org/0000-0003-0078-7897

Editor: Seung Up Kim, Yonsei University College of Medicine, Korea

Received: Oct. 21, 2022 / Received: Oct. 26, 2022 / Accepted: Oct. 26, 2022

Abbreviation:

COVID-19, coronavirus disease 2019